Background The development of metastatic disease throughout the neuroaxis from primary central nervous system (CNS) tumors and non-CNS tumors suggests the cerebrospinal fluid (CSF) is an important source of exposure for chemotherapeutic agents. In non-human primates, a 4-hour, as compared to a 30-minute, topotecan (TPT) infusion prolonged TPT exposure in the CSF Patient and methods We evaluated this approach in a 51-year-old woman with breast cancer metastatic to the CNS TPT was administered at 1 5 mg/m
Introduction
Intrathecal administration of anticancer agents is one method by which concentrations of drugs in the CSF can be enhanced [1] [2] [3] However, practical limitations such as frequency of administration, problems associated with administration in obese patients and small children, risk of infection, and altered CSF flow in patients with ventricular catheters have limited the widespread use of this treatment approach [1, 3] .
Systemic administration of chemotherapeutic agents with high CSF penetration is an alternative approach to enhance cytotoxic exposure in the neuroaxis. Topotecan is a camptothecin analogue that undergoes pH-dependent conversion between active, lactone and inactive, hydroxyacid forms [4, 6] . The standard regimen of topotecan administration is a 30-minute infusion daily for 5 days repeated every 21 days. Topotecan has a relatively high penetration into the CSF (30%-40%), and systemic administration has produced antitumor activity in patients with CNS malignancies [6, 7] . In addition, the antitumor activity of topotecan is associated with maintaining a drug exposure above an exposure threshold for a defined period of time [8] .
Previously, we reported that a four-hour topotecan infusion produced cytotoxic exposure throughout the neuroaxis in a nonhuman primate model (NHP) [4] , In vitro studies were used to evaluate the concentration and length of topotecan exposure associated with 99% inhibition of cell growth (IC99), or exposure duration threshold (EDT) [4, 5] . These results denned the EDTas a topotecan lactone concentration of > 1 ng/ml for eight hours (IC99) daily for five days. To evaluate if this EDT could be attained in the CSF, topotecan was administered as a 30-minute and 4-hour infusion in a nonhuman primate model. At a topotecan lactone plasma exposure (area under the plasma concentration-time curve, AUC) of 56.7 ± 19.9 ng/ml hr, the time above 1 ng/ml in the fourth ventricle was 1.4-fold greater after administration of the 4-hour infusion compared to the 30-minute infusion Moreover, at a topotecan lactone plasma AUC of 140 ng/ml hr, the 4-hour infusion achieved the desired topotecan exposure in the ventricles and lumbar space, whereas the 30-minute infusion failed to achieve this target exposure in the lumbar space.
Although the administration of topotecan as a prolonged infusion for the treatment of primary and metastatic CNS malignancies in the neuroaxis seems promising, the CSF disposition of topotecan after a four-hour infusion in adults has not been evaluated. Thus, we evaluated the systemic, lateral ventricular and lumbar CSF disposition of topotecan after administration of a 30-minute and 4-hour infusion in a patient with breast cancer metastatic to the CNS
Patients and methods

Case history
DW is a 51-year-old patient who was referred from the Department of Gynecology for intrathecal chemotherapy after the first diagnosis of memngeal carcinomatosis from breast cancer Other known metastatic sites were cerebrum, lung, bone, and mediastinal lymph nodes
The patient was diagnosed with bilateral breast cancer (T4b tumors of both breasts) one year before She underwent preoperative neoadjuvant chemotherapy with three cycles of epirubicin (120 mg/m 2 q2w) followed by three cycles of docetaxel (100 mg/m 2 q2w) with a partial remission as best response She then underwent bilateral breast conservative surgery, axillary dissection on the left side, and lymph node sampling on the right side The postoperative tumor classification for both breast carcinomas was ypT4b, ypN2 (2 of 22), MO, G3, R0 As postoperative adjuvant chemotherapy, the patient received 6 cycles of cyclophosphamide 600 mg/m 2 , methotrexate 40 mg/m 2 , and 5-flourouracil 600 mg/m 2 , and radiation therapy to both sides of the thoracic wall During the initial treatment, the patient developed seizures. A cerebral metastasis in the right paneto-occipital region of the brain was diagnosed She was referred to the Department of Radiation Therapy and underwent cranial radiation with an overall dose of 30 Gy Six months later, progressive disease was diagnosed with an enlargement of the right paneto-occipital brain metastasis, two new brain metastases (one left occipital paramedian, one right temporo-occipital), and cerebellar leptomemngeal enhancement suggesting memngeal involvement In addition, the patient developed pulmonary and osseous metastases, and mediastinal lymph node enlargement Due to extreme obesity, intracerebral space occupying lesions, and the associated difficulties with lumbar punctures, an Ommaya reservoir was implanted into the right lateral ventricle without complications Through this reservoir, the patient received 8. 15 mg intrathecal doses of methotrexate every two to three days until no atypical cells were left in the cerebrospinal fluid Topotecan was chosen for subsequent treatment based on its documented activity in preclimcal xenograft models and high degree of CSF penetration
Drug administration and sample collection
During cycle I, topotecan was administered at I 5 mg/m 2 /day as a 30-minute infusion on days 1-4 and as a 4-hour infusion on day 5 Topotecan cycles were repeated every 21 days Due to the development of neutropenic fever on cycle I, the topotecan dose was reduced to 1 0 mg/m 2 /day for cycles 2 and 3 Pharmacokinetic studies were performed on days I and 5 of cycle I, day I of cycle 2, and days I and 5 of cycle 3
After a 30-minute infusion, blood (3 ml) samples were obtained before, and at 0 25, 0 5. 1. 3, and 6 hours after the end of the infusion, lateral ventricular CSF (500 ul) samples were obtained from the Ommaya reservoir before, and at 0 5, 3, and 6 hours after the end of the infusion, and lumbar CSF (500 ul) samples were obtained via lumbar puncture at 0 5 hours after the end of the infusion After a 4-hour infusion, blood (3 ml) samples were obtained before, and at 0.5 hours after the start of the infusion, at the end of the infusion, and 0 5, I, 3, and 6 hours after the end of the infusion, lateral ventricular CSF (500 ul) samples were obtained before, and at 0 5 hours after the start of the infusion, prior to the end of the infusion, and 0 5 and 3 hours after the end of the infusion, and lumbar CSF (500 ul) samples were obtained 0 5 hours after the end of the infusion Blood was placed into hepannized tubes and centnfuged at 2000 x g for two minutes, and the resulting plasma was decanted into a separate tube Then 200 ul of plasma were added to 800 ul of cold methanol (-20
HPLC analysis
Topotecan concentrations in plasma and CSF were measured by an isocratic high-performance liquid chromatography assay using a fluorescence detector The assay was modified from that of Stewart and colleagues, and has been described in detail, previously [7, 9-11] The unmodified methanolic supernatant was used to measure topotecan lactone concentrations Topotecan total (sum of lactone and hydroxy acid) concentrations were measured by adding 20 ul of 20% phosphoric acid to 400 ul of the methanolic solution
Pharmacokinetic analysis
A three-compartment model, with uncoupled-distnbution of the lateral ventricular CSF compartment, was fit to plasma and lateral ventricular CSF concentrations of topotecan using maximum likelihood estimation in ADAPT II [12] Pharmacokinetic parameters estimated included the volume of the central compartment (V C |), intercompartmental rate constants (k, 2 , k2i), elimination rate constant from the central compartment (km), rate constant describing penetration into the ventricular CSF (kn), and elimination rate constant from the ventricular CSF (k 31 ) The volume of the CSF was fixed at 120 ml [4, 13, 14 ] Using standard equations, systemic clearance (CL,y,) and clearance from the ventricular CSF (CI_cs F ) were calculated from parameter estimates [15] Areas under the plasma (AUC PL ) and lateral ventricle CSF (AUCCSF) concentration-time curves from zero to infinity were calculated using the log-trapezoidal method [11, 14] Penetration into the lateral ventnclular CSF was calculated as the ratio of AUC C SF to AUCPL The ratio of lactone AUC PL to total AUC PL , and ratio of lactone AUCCSF '° total AUCCSF were calculated Times above a topotecan lactone and total concentration of 1 ng/ml in the CSF were calculated
Results
Topotecan total plasma and CSF pharmacokinetics
Topotecan total plasma and lateral ventricular CSF concentration-time profiles were prolonged after the 4-hour infusion as compared to the 30-minute infusion (Figure 1 ). The time above a topotecan total concentration > 1 ng/ml in the lateral ventricular CSF was 1.6- (Table 1 ). In addition, the topotecan total concentration in the lumbar CSF was 3-fold higher after administration of the 4-hour (1 5 ng/ml) infusion compared to 30-minute (0.5 ng/ml) infusion.
Topotecan lactone plasma and CSFpharmacokinetics
Topotecan lactone lateral ventricular CSF concentration-time profiles were prolonged after a 4-hour infusion as compared to a 30-minute infusion. Due to logistical difficulties with shipment of samples from Germany, there are no topotecan lactone pharmacokinetic data from days 1 and 5 of cycle 1. The ratio of AUCi actone to AUC totd i was similar in plasma and CSF (Table 1) The time above a topotecan lactone concentration of 1 ng/ml was 1.5-fold longer after a 4-hour infusion as compared to a 30-minute infusion.
Discussion
The exposure of the CNS to anticancer agents is an important consideration in the treatment of metastatic disease throughout the neuroaxis [1, 4] . Although the disposition of topotecan in the CSF after a prolonged infusion has been evaluated in a NHP model, this is the first report in which a 4-hour infusion was compared to a 30-minute infusion for its ability to increase the duration of topotecan exposure in the neuroaxis of an adult with leptomeningeal and cerebral metastatic disease. In this study, prolonging the topotecan infusion from 30 minutes to 4 hours increased the duration of topotecan lactone and total exposure in the lateral ventricular and lumbar CSF. The results of this study are similar to studies evaluating the CSF disposition of topotecan after 30-minute and 4-hour infusions in children with medulloblastoma [16] . In addition, the results of this study were consistent with the previous NHP study, Topotecan total and lactone pharmacokinetic parameters in plasma and lateral ventricular CSF after 30-minute and 4-hour infusions The systemic clearance (CL,y,), clearance from the lateral ventricular CSF (CLi atenl icsF). area under the plasma concentration-time curve (AUC p i alma ), the ratio of topotecan laclone AUC to topotecan total AUC in the plasma and lateral ventricular CSF are reported The percent penetration of topotecan total and lactone into the lateral ventricular CSF, as well as the time topotecan total and lactone concentration were greater than 1 ng/ml in the lateral CSF, are reported " Due to logistical difficulties with shipment of samples from Germany, there is no topotecan lactone pharmacokinetic data after administration of topotecan 30-minute and 4-hour infusions during cycle 1 suggesting that rhesus NHPs are an effective model to optimize treatment strategies for systemic administration of anticancer agents in the treatment of primary and metastatic CNS malignancies. The previous in vitro studies that defined the exposure duration threshold for topotecan (i e , IC 99 > 1 ng/ml for 8 hours) were performed with Daoy and SJ-Med3 medulloblastoma cell lines [7, 16] Thus, the exact target exposure may need to be defined for each disease. Once the specific topotecan EDT has been defined for a malignancy, the PK model can be used to estimate the dose and duration of infusion required to achieve the target exposure in the CSF This reflects the importance of PK modeling in the development of treatment strategies for CNS malignancies. Moreover, the concepts proposed here can be generalized to a variety of primary and metastatic CNS malignancies.
The clinical relevance of this study is underscored by the need to develop new chemotherapeutic agents, novel treatment strategies, and schedules of administration for the treatment of leptomeningeal metastatic disease. Administering topotecan as a four-hour infusion prolonged the duration of drug exposure in the lateral ventricular CSF and achieved concentrations above the cytotoxic threshold. The administration of topotecan as a four-hour infusion may preclude the need for intrathecal administration in the treatment of malignancies throughout the neuroaxis in patients who currently receive systemic as well as intrathecal therapy. Moreover, this study shows the importance of pharmacokinetic modeling and the potential use of pharmacokinetic principles in the development of treatment strategies for CNS malignancies
